Sanofi (FRA:SNW) Valuation Rank


FRA:SNW Sanofi SA FRA:SNW
88 GF Score
Price €75.06
GF Value €106.80
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Sanofi Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Sanofi Valuation Rank Related Terms

FRA:SNW
88GF Score
Sanofi SA FRA:SNW
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sanofi (FRA:SNW) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of €75.06 is trading 29.7% below its estimated GF Value™ of €106.80. GuruFocus considers Sanofi to be Possible Value Trap.

Key valuation signals for FRA:SNW:

  • Valuation Rank:
  • GF Value™: €106.80 vs. price of €75.06 (29.7% below fair value)
  • GF Score™: 88/100 with 2 warning signs

No single metric tells the full story. See the FRA:SNW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
88GF Score

Get the complete analysis for FRA:SNW

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€75.06
Price
€106.80
GF Value